Immunocan completes 250 million RMB Series A financing to accelerate development of world-leading fully human antibody discovery platform

On May 13th, 2026, Shanghai Immunocan Biotech Co., Ltd. (“Immunocan”) announced the successful closing of a RMB 250 million Series A financing. The round was led by Vivo Capital, with participation from Gold Mine Multi Family Office. Existing shareholders, including Kingray Capital and TigerYeah Capital, demonstrated their continued support through follow-on investments. Proceeds will be primarily used to accelerate the continuous R&D of gene-edited animal platforms, advance the commercialization of its fully human antibody rabbit platform, establish the AI-driven antibody drug screening platform, develop scaffold antibodies for complex targets, and support general corporate operations as well as team expansion.

Founded in 2020, Immunocan is dedicated to building next‑generation antibody discovery platforms powered by gene‑editing technologies. The company's proprietary MASIRT® (Massive-fragment Across Species In situ Replacement Technology) has achieved three core breakthroughs: leveraging a linear artificial chromosome strategy that significantly increases gene fragment loading capacity; enabling Mb-scale DNA in situ replacement in a single operation, significantly reducing the number of editing cycles; and demonstrating species-agnostic applicability, with large‑fragment replacement already achieved across multiple species. Beyond its fully human mouse platform, the company has secured a strategic position with its world-first ImmuAlpaca® alpaca-derived antibody mice platform, as well as fully human rabbit and rabbit-derived single heavy-chain antibody rabbits platform, filling critical market gaps in multi-species, high-diversity model animals. The company has completed a comprehensive global patent layout across mainland China, Europe, the U.S., and Japan. The synergy of these triple technological advantages z compresses the construction cycle for fully human antibody platforms while enhancing screening efficiency and success rates, providing high-efficiency source innovation tools for antibody drug R&D. Simultaneously, the company is advancing its MabAI®  platform. It develops AI-driven antibody generation and characterization models based on high-quality multi-species immune datasets that yield over 100 million sequences annually, substantially boosting screening efficiency and developability and forming a dual-engine innovation system of "Fully Human Model Animals + AI Empowerment."

Immunocan has established a robust collaborative network with leading domestic and international pharmaceutical companies, including several Global Top 10 MNCs. The industrial value of its platforms has been rigorously validated by these tier-one partners. Meanwhile, the company is actively expanding diversified application scenarios for its platform technologies with multiple biotechnology enterprises.